Monitoring of effects of cis-diamminedichloroplatinum II. Part I. Cytogenetic analysis in vitro.
The cytogenetic effects of cytostatic drug Platidiam Lachema (cis-diamminedichloroplatinum (II) complex, cis-DDP) have been studied employing short-term in vitro cultivation of human peripheral lymphocytes. Three hours following the administration of cis-DDP at a concentration of 12.5 microM (that is a concentration approximately 10 times lower than that applied clinically at a single dose), chromosome aberrations (predominantly breaks, in 73% those of the chromatid type) were seen at an increased rate. They reached their maximum after 24 h of treatment. A time dependence has been revealed: with decreasing mitotic activity and prolonged time of cis-DDP treatment (3, 6, 18, 24, 48, 72 h, respectively) the number of cells with aberrant chromosomes increased, this elevation being statistically significant from 18 h on.
D002478:Cells, Cultured; D002869:Chromosome Aberrations; D002945:Cisplatin / Q000494:pharmacology*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D008938:Mitosis / Q000187:drug effects; D013997:Time Factors
D002945:Cisplatin